Find disease awareness content and relevant supporting materials
Post-market study with Rezu?m Radiofrequency System in benign prostatic hyperplasia published in Research and Reports in Urology.-NxThera.
NxThera announced that new data from the first post-market clinical evaluation of its minimally invasive Rezu?m Radiofrequency System demonstrated significant,...
Teleflex announces positive data showing that the UroLift System treating lower urinary tract symptoms due to benign prostatic hyperplasia relieves enlarged prostate symptoms while preserving patients’ sexual function.
Teleflex Incorporated announced that data from two analyses of the UroLift System were presented at the American Urological Association (AUA) 2020 Virtual Science event.
Silodosin 8 mg improves benign prostatic obstruction in Caucasian patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: results from an explorative clinical study.
To preliminary investigate the effects of silodosin 8 mg once daily on obstruction urodynamic parameters and subjective symptoms in Caucasian patients with lower urinary tract symptoms suggestive of benign prostatic enlargement.
Teleflex announces large-scale analysis of real-world healthcare claims data for enlarged prostate procedures
Teleflex Incorporated announced that new real-world healthcare claims data reveal that the risk of return procedures is lowest after treatment with the UroLift System among the analyzed benign prostatic hyperplasia (BPH) treatment options. The data also show that the risk of surgical retreatment is similar between UroLift PUL, TURP and GreenLight PVP while highest following Rezum Water Vapor Therapy.